SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: ACRS = MC $44 M / Cash $115 M/ Phase 3 readout imminent

01 Oct 2019 10:21 AM <--
12 Sep 2019 12:13 PM

Return to ACRS = MC $44 M / Cash $115 M/ Phase 3 readout imminent
 
BRUTAL Hot Rebound Play which is massive underpriced here trading wayyy below cash ....

Market Cap $43 M / Cash $115 M or untill end 2021 / 2 Marketed Product / 1 Phase 3 trial (common warts) with results expected in Q4 2019 and many other phase 2 programs / because of their strategic change they wants to out-license all their Products which means HUGE upfront payments for the company (more infos below)= CHEAPEST Biotech you can get at this time

Aclaris Therapeutics (ACRS)

Market Cap: $43 M
Cash: $115 M or enough untill end 2021

Price $1.07

Aclaris Therapeutics Announces New Strategic Direction
investor.aclaristx.com

ACRS aquired a attractive drug from Allergan last year paid $65 m upfront alone for this drug which they now looking to outlicense .
globenewswire.com

Pipeline

aclaristx.com

Largest Shareholders:

Deerfield Management Company LP...5 893 416
Franklin Advisers, Inc....3 953 203
BlackRock Fund Advisors ...2 359 223
Broadfin Capital LLC...2 280 260
D. E. Shaw & Co. LP....2 049 462
Sofinnova Ventures, Inc.....1 911 573
Vivo Capital LLC ....1 647 214
Fidelity Management & Research Co...1 562 190
Polar Capital LLP...1 443 920
The Vanguard Group, Inc...1 142 022